UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients

Launched by LIVEKIDNEY.BIO · Dec 15, 2024

Keywords

ClinConnect Summary

The UC-MSC Cell Therapy Study is a clinical trial designed to explore the safety and effectiveness of a new treatment using umbilical cord mesenchymal stem cells (UC-MSCs) for adults with systemic lupus erythematosus (SLE), a condition that can affect various organs in the body, including the kidneys. The main goals of this study are to determine if UC-MSCs can help improve kidney function and reduce disease activity in people with SLE, while also ensuring that the treatment is safe and well-tolerated.

To participate in this trial, individuals must be between 18 and 75 years old and have a diagnosis of SLE, verified by specific criteria. Participants will receive a single dose of UC-MSCs along with their regular treatment and will attend regular clinic visits for health assessments. During these visits, they will provide blood and urine samples, undergo physical exams, and have their kidney health monitored. The study is currently recruiting, and it aims to provide valuable insights into new treatment options for SLE and lupus-related kidney problems.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • 1. Age 18-75 years at the time of screening
• • 2. Diagnosis of systemic lupus erythematosus (SLE), meeting at least 4 of the 11 criteria included in the American College of Rheumatology (ACR) Classification Criteria and/or 4 of the 17 criteria (with at least one of those being clinical and at least one being immunologic) included in the Systemic Lupus International Collaborating Clinics (SLICC) Criteria, at the screening visit.
• • 3. Must have a positive ANA (≥1:160 titer) or positive anti-dsDNA antibody test within 6 months of the screening visit
• • 4. An eGFR of ≥ 30 mL/min/1.73 m2 in the screening period
• • 5. Prior SLE background therapy with at least one non-biologic medication (e.g. immunosuppressant and/or antimalarial), not including corticosteroids, is required for ≥ 12 weeks before the screening visit.
• • 6. SLEDAI-2K ≥6 at the time of screening
• • 7. Participant able and willing to provide written informed consent
• • 8. Must be able and willing to adhere to the study visit schedule and other protocol requirements.
• • Exclusion Criteria
• • 1. History of any non-systemic lupus erythematosus (non-SLE) disease that required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the 12 weeks preceding the screening visit.
• • 2. History of dialysis within 12 months prior to the screening visit or expected need for renal replacement therapy (dialysis or renal transplant) within a six-month period after enrollment.
• • 3. Use of prednisone \>0.5 mg/kg/day (or equivalent corticosteroid) in the 4 weeks prior to the screening visit.
• • 4. Any change or addition to a non-biologic immunosuppressant and/ or antimalarial regimen (not including corticosteroids) ≤ 12 weeks prior to the Screening visit.
• • 5. Treatment with an interventional agent within the washout time of 90 days or 5 half-lives prior to Baseline (Day 0), whichever is longer.
• • 6. Receipt of any commercially available biologic agent within the washout period described above prior to Baseline (Day 0).
• • 7. Receipt of prior MSC therapy within the washout time of 52 weeks prior to Baseline (Day 0).
• • 8. Previous treatment with any type of cellular therapy e.g., Tregs or CAR-T cells, with the exception of previous MSCs.
• • 9. Major surgery within 90 days prior to Baseline (Day 0) or major surgery planned during the study period
• • 10. Confirmed positive test for active hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or tuberculosis (TB).
• • 11. Any active infection that has not been adequately treated or completely resolved prior to Baseline (Day 0).
• • 12. History of cancer, apart from adequately treated squamous or basal cell carcinoma of the skin, or cervical carcinoma in situ
• • 13. Pregnant or breast-feeding women and women with intention to become pregnant/to breast-feed during the duration of the trial.
• • 14. Women and men who do not agree to use a medically acceptable form of contraception for the duration of the trial.
• • 15. Any other comorbidity which may render the participant unfit for study participation according to the investigator's judgement.
• • 16. Any other medical condition, which in the opinion of the investigator, may impact the quality or interpretation of the data obtained from the study.